Open access
Aug 2026
Trametinib-mediated MEK inhibition impairs cancer cell viability and invasion in patient-derived tumor avatars of glioblastoma with extraneural metastases: A proof-of-concept study.
A rare clinical case of metastatic GBM is described and proof-of-concept evidence that MEK pathway inhibition may represent a potential therapeutic vulnerability to counteract rapid tumor spread and improve responsiveness to temzolomide in this individual metastatic GBM case is highlighted.
M. Novak, B. Majc, M. Vidmar et al.
· Biomedicine & pharmacotherap... · 0 citations